{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T13:19:23Z","timestamp":1791983963296,"version":"4.4.0"},"reference-count":84,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,10]],"date-time":"2024-10-10T00:00:00Z","timestamp":1728518400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R35 GM131839"],"award-info":[{"award-number":["R35 GM131839"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["NIH U01 NS114098"],"award-info":[{"award-number":["NIH U01 NS114098"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 NS106245"],"award-info":[{"award-number":["R01 NS106245"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["S10 OD020012"],"award-info":[{"award-number":["S10 OD020012"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 NS104022"],"award-info":[{"award-number":["R01 NS104022"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005725","name":"CHDI Foundation Los Angeles","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Nucleic Acids"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.omtn.2024.102359","type":"journal-article","created":{"date-parts":[[2024,10,15]],"date-time":"2024-10-15T11:30:08Z","timestamp":1728991808000},"page":"102359","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"title":["Preventing acute neurotoxicity of CNS therapeutic oligonucleotides with the addition of Ca2+ and Mg2+ in the formulation"],"prefix":"10.1016","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4594-0640","authenticated-orcid":false,"given":"Rachael","family":"Miller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Paquette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Barker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen","family":"Sapp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"McHugh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brianna","family":"Bramato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nozomi","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Alterman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimas","family":"Echeveria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Watts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christelle","family":"Anaclet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marian","family":"DiFiglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6928-8071","authenticated-orcid":false,"given":"Anastasia","family":"Khvorova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Aronin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omtn.2024.102359_bib1","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1093\/nar\/gkad067","article-title":"Chemistry, structure and function of approved oligonucleotide therapeutics","volume":"51","author":"Egli","year":"2023","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omtn.2024.102359_bib2","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1016\/j.jhep.2023.06.013","article-title":"Efficacy and safety of givosiran for acute hepatic porphyria: Final results of the randomized phase III ENVISION trial","volume":"79","author":"Kuter","year":"2023","journal-title":"J.\u00a0Hepatol."},{"key":"10.1016\/j.omtn.2024.102359_bib3","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","article-title":"Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy","volume":"377","author":"Finkel","year":"2017","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.omtn.2024.102359_bib4","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1089\/nat.2023.0027","article-title":"From Failure to Meet the Clinical Endpoint to U.S. Food and Drug Administration Approval: 15th Antisense Oligonucleotide Therapy Approved Qalsody (Tofersen) for Treatment of SOD1 Mutated Amyotrophic Lateral Sclerosis","volume":"33","author":"van Roon-Mom","year":"2023","journal-title":"Nucleic Acid Therapeut."},{"key":"10.1016\/j.omtn.2024.102359_bib5","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1056\/NEJMoa2204705","article-title":"Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS","volume":"387","author":"Miller","year":"2022","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.omtn.2024.102359_bib6","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1056\/NEJMc2300400","article-title":"Tominersen in Adults with Manifest Huntington's Disease","volume":"389","author":"McColgan","year":"2023","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.omtn.2024.102359_bib7","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/d41573-023-00001-3","article-title":"2022 FDA approvals","volume":"22","author":"Mullard","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.omtn.2024.102359_bib8","article-title":"Antisense Oligonucleotides: An Emerging Area in Drug Discovery and Development","volume":"9","author":"Dhuri","year":"2020","journal-title":"J.\u00a0Clin. Med."},{"key":"10.1016\/j.omtn.2024.102359_bib9","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1146\/annurev.pharmtox.010909.105654","article-title":"RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform","volume":"50","author":"Bennett","year":"2010","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.omtn.2024.102359_bib10","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1021\/mp200250f","article-title":"Palmitic acid-conjugated 21-nucleotide siRNA enhances gene-silencing activity","volume":"8","author":"Kubo","year":"2011","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.omtn.2024.102359_bib11","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1038\/s41587-022-01334-x","article-title":"Expanding RNAi therapeutics to extrahepatic tissues with lipophilic conjugates","volume":"40","author":"Brown","year":"2022","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.omtn.2024.102359_bib12","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1038\/s41587-019-0205-0","article-title":"A divalent siRNA chemical scaffold for potent and sustained modulation of gene expression throughout the central nervous system","volume":"37","author":"Alterman","year":"2019","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.omtn.2024.102359_bib13","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.152203","article-title":"Comparative route of administration studies using therapeutic siRNAs show widespread gene modulation in Dorset sheep","volume":"6","author":"Ferguson","year":"2021","journal-title":"JCI Insight"},{"key":"10.1016\/j.omtn.2024.102359_bib34","first-page":"189","article-title":"Efficacy of tribromoethanol anesthesia in mice","volume":"43","author":"Papaioannou","year":"1993","journal-title":"Lab. Anim. Sci."},{"key":"10.1016\/j.omtn.2024.102359_bib14","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2003715","article-title":"Phase 1-2 Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS","volume":"383","author":"Miller","year":"2020","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.omtn.2024.102359_bib15","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.omtn.2022.12.010","article-title":"Change of intracellular calcium level causes acute neurotoxicity by antisense oligonucleotides via CSF route","volume":"31","author":"Jia","year":"2023","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.omtn.2024.102359_bib16","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1089\/nat.2021.0071","article-title":"Acute Neurotoxicity of Antisense Oligonucleotides After Intracerebroventricular Injection Into Mouse Brain Can Be Predicted from Sequence Features","volume":"32","author":"Hagedorn","year":"2022","journal-title":"Nucleic Acid Therapeut."},{"key":"10.1016\/j.omtn.2024.102359_bib17","doi-asserted-by":"crossref","first-page":"169","DOI":"10.3233\/JHD-239001","article-title":"Huntington's Disease Clinical Trials Corner: August 2023","volume":"12","author":"Estevez-Fraga","year":"2023","journal-title":"J.\u00a0Huntingtons Dis."},{"key":"10.1016\/j.omtn.2024.102359_bib18","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3233\/JHD-229003","article-title":"Perspective: Tominersen Testing Finds a Way Forward","volume":"11","author":"Aronin","year":"2022","journal-title":"J.\u00a0Huntingtons Dis."},{"key":"10.1016\/j.omtn.2024.102359_bib19","article-title":"Quantifying and Mitigating Motor Phenotypes Induced by Antisense Oligonucleotides in the Central Nervous System","author":"Moazami","year":"2021","journal-title":"bioRxiv"},{"key":"10.1016\/j.omtn.2024.102359_bib20","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1146\/annurev-biochem-060409-092720","article-title":"Understanding nucleic acid-ion interactions","volume":"83","author":"Lipfert","year":"2014","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.omtn.2024.102359_bib21","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/j.bpj.2019.08.007","article-title":"Quantitative Studies of an RNA Duplex Electrostatics by Ion Counting","volume":"117","author":"Gebala","year":"2019","journal-title":"Biophys. J."},{"key":"10.1016\/j.omtn.2024.102359_bib22","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1261\/rna.5205404","article-title":"A guide to ions and RNA structure","volume":"10","author":"Draper","year":"2004","journal-title":"RNA"},{"key":"10.1016\/j.omtn.2024.102359_bib23","doi-asserted-by":"crossref","first-page":"17105","DOI":"10.1021\/bi982201+","article-title":"Divalent cations stabilize unstacked conformations of DNA and RNA by interacting with base pi systems","volume":"37","author":"McFail-Isom","year":"1998","journal-title":"Biochemistry"},{"key":"10.1016\/j.omtn.2024.102359_bib24","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1006\/jmbi.1997.1383","article-title":"Affinities and selectivities of divalent cation binding sites within an RNA tertiary structure","volume":"273","author":"Bukhman","year":"1997","journal-title":"J.\u00a0Mol. Biol."},{"key":"10.1016\/j.omtn.2024.102359_bib25","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1016\/j.ymthe.2018.03.019","article-title":"Hydrophobicity of Lipid-Conjugated siRNAs Predicts Productive Loading to Small Extracellular Vesicles","volume":"26","author":"Biscans","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2024.102359_bib26","doi-asserted-by":"crossref","first-page":"7665","DOI":"10.1093\/nar\/gkaa595","article-title":"The chemical structure and phosphorothioate content of hydrophobically modified siRNAs impact extrahepatic distribution and efficacy","volume":"48","author":"Biscans","year":"2020","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omtn.2024.102359_bib27","doi-asserted-by":"crossref","DOI":"10.1038\/mtna.2016.50","article-title":"Docosahexaenoic Acid Conjugation Enhances Distribution and Safety of siRNA upon Local Administration in Mouse Brain","volume":"5","author":"Nikan","year":"2016","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.omtn.2024.102359_bib28","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1056\/NEJMoa1900907","article-title":"Targeting Huntingtin Expression in Patients with Huntington's Disease","volume":"380","author":"Tabrizi","year":"2019","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.omtn.2024.102359_bib29","article-title":"Huntington disease","volume":"1","author":"Bates","year":"2015","journal-title":"Nat. Rev. Dis. Prim."},{"key":"10.1016\/j.omtn.2024.102359_bib30","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/j.neuron.2016.02.003","article-title":"The Biology of Huntingtin","volume":"89","author":"Saudou","year":"2016","journal-title":"Neuron"},{"key":"10.1016\/j.omtn.2024.102359_bib31","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1002\/mds.26020","article-title":"Huntingtin-lowering strategies in Huntington's disease: antisense oligonucleotides, small RNAs, and gene editing","volume":"29","author":"Aronin","year":"2014","journal-title":"Mov. Disord."},{"key":"10.1016\/j.omtn.2024.102359_bib32","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1126\/science.aba4624","article-title":"Antisense oligonucleotides for neurodegeneration","volume":"367","author":"Leavitt","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.omtn.2024.102359_bib33","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.3390\/biomedicines11051461","article-title":"Cerebrospinal Fluid-Basic Concepts Review","volume":"11","author":"Czarniak","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.omtn.2024.102359_bib35","article-title":"Extended Nucleic Acid (exNA): A Novel, Biologically Compatible Backbone that Significantly Enhances Oligonucleotide Efficacy in\u00a0vivo","author":"Yamada","year":"2023","journal-title":"bioRxiv"},{"key":"10.1016\/j.omtn.2024.102359_bib36","doi-asserted-by":"crossref","first-page":"5802","DOI":"10.1038\/s41467-022-33061-x","article-title":"Chemical engineering of therapeutic siRNAs for allele-specific gene silencing in Huntington's disease models","volume":"13","author":"Conroy","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omtn.2024.102359_bib37","doi-asserted-by":"crossref","first-page":"5168","DOI":"10.1523\/JNEUROSCI.2955-17.2018","article-title":"Genetic Activation, Inactivation, and Deletion Reveal a Limited And Nuanced Role for Somatostatin-Containing Basal Forebrain Neurons in Behavioral State Control","volume":"38","author":"Anaclet","year":"2018","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.omtn.2024.102359_bib38","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1038\/nn.3789","article-title":"The GABAergic parafacial zone is a medullary slow wave sleep-promoting center","volume":"17","author":"Anaclet","year":"2014","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.omtn.2024.102359_bib39","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/npp.2017.152","article-title":"Activation of the GABAergic Parafacial Zone Maintains Sleep and Counteracts the Wake-Promoting Action of the Psychostimulants Armodafinil and Caffeine","volume":"43","author":"Anaclet","year":"2018","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.omtn.2024.102359_bib40","doi-asserted-by":"crossref","first-page":"8744","DOI":"10.1038\/ncomms9744","article-title":"Basal forebrain control of wakefulness and cortical rhythms","volume":"6","author":"Anaclet","year":"2015","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omtn.2024.102359_bib41","doi-asserted-by":"crossref","first-page":"755","DOI":"10.3389\/fnins.2019.00755","article-title":"Differential Role of Pontomedullary Glutamatergic Neuronal Populations in Sleep-Wake Control","volume":"13","author":"Erickson","year":"2019","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.omtn.2024.102359_bib42","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1111\/j.1471-4159.1986.tb13082.x","article-title":"Homeostasis of brain and cerebrospinal fluid calcium concentrations during chronic hypo- and hypercalcemia","volume":"47","author":"Murphy","year":"1986","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.omtn.2024.102359_bib43","first-page":"297","article-title":"A study of calcium and magnesium in the cerebrospinal fluid","volume":"27","author":"Harris","year":"1955","journal-title":"Yale J. Biol. Med."},{"key":"10.1016\/j.omtn.2024.102359_bib45","first-page":"402","article-title":"Evaluation of some pharmaceutical aspects of intrathecal methotrexate sodium, cytarabine and hydrocortisone sodium succinate","volume":"35","author":"Cradock","year":"1978","journal-title":"Am. J. Hosp. Pharm."},{"key":"10.1016\/j.omtn.2024.102359_bib46","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.1016\/j.celrep.2018.07.106","article-title":"Nuclear Localization of Huntingtin mRNA Is Specific to Cells of Neuronal Origin","volume":"24","author":"Didiot","year":"2018","journal-title":"Cell Rep."},{"key":"10.1016\/j.omtn.2024.102359_bib47","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1089\/nat.2014.0506","article-title":"Phosphorothioates, essential components of therapeutic oligonucleotides","volume":"24","author":"Eckstein","year":"2014","journal-title":"Nucleic Acid Therapeut."},{"key":"10.1016\/j.omtn.2024.102359_bib48","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1093\/nar\/gkg147","article-title":"Tolerance for mutations and chemical modifications in a siRNA","volume":"31","author":"Amarzguioui","year":"2003","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omtn.2024.102359_bib49","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1089\/108729003321629638","article-title":"Sequence, chemical, and structural variation of small interfering RNAs and short hairpin RNAs and the effect on mammalian gene silencing","volume":"13","author":"Harborth","year":"2003","journal-title":"Antisense Nucleic Acid Drug Dev."},{"key":"10.1016\/j.omtn.2024.102359_bib50","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.omtn.2017.07.003","article-title":"Strategies for In\u00a0Vivo Screening and Mitigation of Hepatotoxicity Associated with Antisense Drugs","volume":"8","author":"Kamola","year":"2017","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.omtn.2024.102359_bib51","doi-asserted-by":"crossref","first-page":"4882","DOI":"10.1093\/nar\/gku142","article-title":"Sequence motifs associated with hepatotoxicity of locked nucleic acid--modified antisense oligonucleotides","volume":"42","author":"Burdick","year":"2014","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omtn.2024.102359_bib52","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1002\/cmdc.201000156","article-title":"Off-target effects related to the phosphorothioate modification of nucleic acids","volume":"5","author":"Winkler","year":"2010","journal-title":"ChemMedChem"},{"key":"10.1016\/j.omtn.2024.102359_bib53","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1093\/nar\/gky060","article-title":"Acute hepatotoxicity of 2' fluoro-modified 5-10-5 gapmer phosphorothioate oligonucleotides in mice correlates with intracellular protein binding and the loss of DBHS proteins","volume":"46","author":"Shen","year":"2018","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omtn.2024.102359_bib54","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1261\/rna.060079.116","article-title":"Unraveling Mg(2+)-RNA binding with atomistic molecular dynamics","volume":"23","author":"Cunha","year":"2017","journal-title":"RNA"},{"key":"10.1016\/j.omtn.2024.102359_bib55","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/nbt.3765","article-title":"The chemical evolution of oligonucleotide therapies of clinical utility","volume":"35","author":"Khvorova","year":"2017","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.omtn.2024.102359_bib56","doi-asserted-by":"crossref","first-page":"12069","DOI":"10.1093\/nar\/gkab1126","article-title":"Structurally constrained phosphonate internucleotide linkage impacts oligonucleotide-enzyme interaction, and modulates siRNA activity and allele specificity","volume":"49","author":"Yamada","year":"2021","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omtn.2024.102359_bib57","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1089\/nat.2023.0068","article-title":"Nucleic Acid Therapeutics: Successes, Milestones, and Upcoming Innovation","volume":"34","author":"Belgrad","year":"2024","journal-title":"Nucleic Acid Therapeut."},{"key":"10.1016\/j.omtn.2024.102359_bib58","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/s41573-024-00912-9","article-title":"RNAi-based drug design: considerations and future directions","volume":"23","author":"Tang","year":"2024","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.omtn.2024.102359_bib59","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1113\/jphysiol.1957.sp005808","article-title":"The action of calcium on the electrical properties of squid axons","volume":"137","author":"Frankenhaeuser","year":"1957","journal-title":"J.\u00a0Physiol."},{"key":"10.1016\/j.omtn.2024.102359_bib60","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1113\/jphysiol.1958.sp006022","article-title":"The effect of magnesium and calcium on the frog myelinated nerve fibre","volume":"142","author":"Frankenhaeuser","year":"1958","journal-title":"J.\u00a0Physiol."},{"key":"10.1016\/j.omtn.2024.102359_bib61","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1085\/jgp.82.6.785","article-title":"Simple shifts in the voltage dependence of sodium channel gating caused by divalent cations","volume":"82","author":"Hahin","year":"1983","journal-title":"J.\u00a0Gen. Physiol."},{"key":"10.1016\/j.omtn.2024.102359_bib62","doi-asserted-by":"crossref","DOI":"10.1177\/1759091415578050","article-title":"Hypocalcemia-induced seizure: demystifying the calcium paradox","volume":"7","author":"Han","year":"2015","journal-title":"ASN Neuro"},{"key":"10.1016\/j.omtn.2024.102359_bib63","doi-asserted-by":"crossref","first-page":"2607","DOI":"10.1093\/brain\/awae168","article-title":"Failure of C9orf72 sense repeat-targeting antisense oligonucleotides: lessons learned and the path forward","volume":"147","author":"Cammack","year":"2024","journal-title":"Brain"},{"key":"10.1016\/j.omtn.2024.102359_bib64","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1007\/s13311-022-01247-2","article-title":"Antisense Oligonucleotides for the Study and Treatment of ALS","volume":"19","author":"Boros","year":"2022","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.omtn.2024.102359_bib65","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1038\/s41467-021-21112-8","article-title":"Variant-selective stereopure oligonucleotides protect against pathologies associated with C9orf72-repeat expansion in preclinical models","volume":"12","author":"Liu","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omtn.2024.102359_bib66","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.omtn.2022.04.007","article-title":"Preclinical evaluation of WVE-004, aninvestigational stereopure oligonucleotide forthe treatment of C9orf72-associated ALS or FTD","volume":"28","author":"Liu","year":"2022","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.omtn.2024.102359_bib67","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1001\/jamaneurol.2022.2909","article-title":"Evaluating the Safety and Efficacy of Crenezumab vs Placebo in Adults With Early Alzheimer Disease: Two Phase 3 Randomized Placebo-Controlled Trials","volume":"79","author":"Ostrowitzki","year":"2022","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.omtn.2024.102359_bib68","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1056\/NEJMoa2304430","article-title":"Two Phase 3 Trials of Gantenerumab in Early Alzheimer's Disease","volume":"389","author":"Bateman","year":"2023","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.omtn.2024.102359_bib69","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.chembiol.2023.09.005","article-title":"Targeting RNA with synthetic oligonucleotides: Clinical success invites new challenges","volume":"31","author":"Hofman","year":"2024","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.omtn.2024.102359_bib70","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1056\/NEJMoa1813279","article-title":"Patient-Customized Oligonucleotide Therapy for a Rare Genetic Disease","volume":"381","author":"Kim","year":"2019","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.omtn.2024.102359_bib71","doi-asserted-by":"crossref","DOI":"10.3390\/genes15070821","article-title":"Preparing for Patient-Customized N-of-1 Antisense Oligonucleotide Therapy to Treat Rare Diseases","volume":"15","author":"Wilton-Clark","year":"2024","journal-title":"Genes"},{"key":"10.1016\/j.omtn.2024.102359_bib72","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/s41591-021-01615-z","article-title":"Antisense oligonucleotide silencing of FUS expression as a therapeutic approach in amyotrophic lateral sclerosis","volume":"28","author":"Korobeynikov","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.omtn.2024.102359_bib73","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1016\/j.ymthe.2023.05.006","article-title":"Di-valent siRNA-mediated silencing of MSH3 blocks somatic repeat expansion in mouse models of Huntington's disease","volume":"31","author":"O'Reilly","year":"2023","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2024.102359_bib74","doi-asserted-by":"crossref","first-page":"5235","DOI":"10.1093\/nar\/gkaa299","article-title":"Phosphorothioate modified oligonucleotide-protein interactions","volume":"48","author":"Crooke","year":"2020","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omtn.2024.102359_bib75","doi-asserted-by":"crossref","first-page":"10865","DOI":"10.1093\/nar\/gkz771","article-title":"Kinetic and subcellular analysis of PS-ASO\/protein interactions with P54nrb and RNase H1","volume":"47","author":"Vickers","year":"2019","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omtn.2024.102359_bib76","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.omtn.2019.11.020","article-title":"Identifying and Avoiding tcDNA-ASO Sequence-Specific Toxicity for the Development of DMD Exon 51 Skipping Therapy","volume":"19","author":"Aupy","year":"2020","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.omtn.2024.102359_bib77","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1089\/nat.2020.0923","article-title":"Solid-Phase Separation of Toxic Phosphorothioate Antisense Oligonucleotide-Protein Nucleolar Aggregates Is Cytoprotective","volume":"31","author":"Liang","year":"2021","journal-title":"Nucleic Acid Therapeut."},{"key":"10.1016\/j.omtn.2024.102359_bib78","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/s41573-021-00162-z","article-title":"Antisense technology: an overview and prospectus","volume":"20","author":"Crooke","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.omtn.2024.102359_bib79","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/0143-4160(83)90047-7","article-title":"A survey of readily available chelators for buffering calcium ion concentrations in physiological solutions","volume":"4","author":"Durham","year":"1983","journal-title":"Cell Calcium"},{"key":"10.1016\/j.omtn.2024.102359_bib80","author":"Dawson"},{"key":"10.1016\/j.omtn.2024.102359_bib81","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1093\/hmg\/ddg169","article-title":"Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease","volume":"12","author":"Slow","year":"2003","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.omtn.2024.102359_bib82","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/j.neuron.2022.01.006","article-title":"Uninterrupted CAG repeat drives striatum-selective transcriptionopathy and nuclear pathogenesis in human Huntingtin BAC mice","volume":"110","author":"Gu","year":"2022","journal-title":"Neuron"},{"key":"10.1016\/j.omtn.2024.102359_bib83","series-title":"The Mouse Brain in Stereotaxic Coordinates","author":"Paxinos","year":"2001"},{"key":"10.1016\/j.omtn.2024.102359_bib84","series-title":"The Mouse Brain in Stereotaxic Coordinates","author":"Keith","year":"2008"},{"key":"10.1016\/j.omtn.2024.102359_bib85","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/0896-6273(95)90346-1","article-title":"Huntingtin is a cytoplasmic protein associated with vesicles in human and rat brain neurons","volume":"14","author":"DiFiglia","year":"1995","journal-title":"Neuron"}],"container-title":["Molecular Therapy Nucleic Acids"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162253124002464?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162253124002464?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T09:56:07Z","timestamp":1778838967000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2162253124002464"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":84,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["S2162253124002464"],"URL":"https:\/\/doi.org\/10.1016\/j.omtn.2024.102359","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2024.06.06.597639","asserted-by":"object"}]},"ISSN":["2162-2531"],"issn-type":[{"value":"2162-2531","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Preventing acute neurotoxicity of CNS therapeutic oligonucleotides with the addition of Ca2+ and Mg2+ in the formulation","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Nucleic Acids","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omtn.2024.102359","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}],"article-number":"102359"}}